Estadístiques de Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria
Visites totals
| views | |
|---|---|
| Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria | 60 |
Visites totals per mes
| views | |
|---|---|
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 2 |
| April 2025 | 0 |
Visites al fitxer
| views | |
|---|---|
| Maurer_jaci_remi.pdf(legacy) | 84 |
| Maurer_jaci_remi.pdf | 42 |
Vistes principals per país
| views | |
|---|---|
| United States | 43 |
| Spain | 5 |
| Ireland | 4 |
| South Korea | 3 |
| Japan | 2 |
| Australia | 1 |
| Belgium | 1 |
| Mongolia | 1 |
Visites principals per ciutat
| views | |
|---|---|
| Boardman | 8 |
| Mountain View | 6 |
| Ann Arbor | 5 |
| San Ramon | 5 |
| Dublin | 4 |
| Cambridge | 3 |
| Fairfield | 3 |
| Barcelona | 2 |
| Daegu | 2 |
| Menlo Park | 2 |
| Tokyo | 2 |
| Ashburn | 1 |
| Kensington | 1 |
| Parsippany | 1 |
| Puebla De Trives | 1 |
| Ripollet | 1 |
| Rochester | 1 |
| Seongnam | 1 |
| Sükhbaatar | 1 |